Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Jianqin Shan"'
Autor:
Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Barry Storer, Sherry Pierce, Jianqin Shan, Stephan Faderl, Elihu H. Estey
Publikováno v:
Haematologica, Vol 98, Iss 1 (2013)
We recently reported that clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (GCLAC) produced a 46% complete remission rate in relapsed/refractory acute myeloid leukemia. GCLAC differs from FLAG by substitution of clofarabin
Externí odkaz:
https://doaj.org/article/6cea6b8f821348d5a39a4bc87ddfe834
Autor:
Naveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, William Wierda, Susan O’Brien, Jorge Cortes
Publikováno v:
Haematologica, Vol 97, Iss 7 (2012)
Background Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients.Design and Methods We reviewed all 468
Externí odkaz:
https://doaj.org/article/b3ea3e9ade2449fc9c8c00e34ef2eac6
Autor:
Alfonso Quintás-Cardama, Hagop Kantarjian, Susan O’Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Jianqin Shan, Jorge Cortes
Publikováno v:
Haematologica, Vol 96, Iss 6 (2011)
We investigated the impact of carrying more than one BCR-ABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than o
Externí odkaz:
https://doaj.org/article/0981f67e290741a386cd3b37ea00ce98
Autor:
Guillermo Garcia-Manero, Jianqin Shan, Stefan Faderl, Hagop M. Kantarjian, Jorge E. Cortes, Farhad Ravandi, Elias Jabbour, Susan O'Brien
Publikováno v:
Cancer. 118:3116-3122
BACKGROUND: The long-term outcome of patients with chronic phase chronic myeloid leukemia treated with imatinib after failure of interferon alpha therapy has not been detailed. METHODS: In total, 368 patients were analyzed. Univariate and multivariat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ab76625806f3800c9188325a6433f4b
https://doi.org/10.1002/cncr.26568
https://doi.org/10.1002/cncr.26568
Autor:
Farhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, Stefan Faderl, Jianqin Shan, Elias Jabbour, Tapan M. Kadia, William G. Wierda, Carlos E. Bueso-Ramos, Wei Gang Tong, Alfonso Quintás-Cardama, Hagop M. Kantarjian, Gautam Borthakur
Publikováno v:
Cancer. 118:4462-4470
Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d85984bbd97864366aaf4ba1625ea39
https://doi.org/10.1002/cncr.27420
https://doi.org/10.1002/cncr.27420
Autor:
Guillermo Garcia-Manero, Mary Beth Rios, Susan O'Brien, Elias Jabbour, Alfonso Quintás-Cardama, Jianqin Shan, Hagop M. Kantarjian, Jorge E. Cortes
Publikováno v:
Journal of Clinical Oncology. 29:4260-4265
Purpose The response definitions proposed by the European LeukemiaNet (ELN) are defined on the basis of imatinib front-line therapy. It is unknown whether these definitions apply to patients treated with second-generation tyrosine kinase inhibitors (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81bf193b445aea1bb56b5a5a9a5586d4
https://doi.org/10.1200/jco.2011.36.0693
https://doi.org/10.1200/jco.2011.36.0693
Autor:
Elihu H. Estey, Hagop M. Kantarjian, Stephan Faderl, Jianqin Shan, Barry E. Storer, Andrei R. Shustov, Stephen H. Petersdorf, Sherry Pierce, Derek L. Stirewalt, John M. Pagel, Paul C. Hendrie, Elizabeth Harrington, Frederick R. Appelbaum, Pamela S. Becker
Publikováno v:
British Journal of Haematology. 155:182-189
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffb0cff6e93ac74b1539b7d242972b11
https://doi.org/10.1111/j.1365-2141.2011.08831.x
https://doi.org/10.1111/j.1365-2141.2011.08831.x
Autor:
Kiran Naqvi, Xiudong Lei, Sherry Pierce, Maria E. Suarez-Almazor, Jeong Hoon Oh, Hagop M. Kantarjian, Jianqin Shan, Guillermo Garcia-Manero, Carlos E. Vigil, Sagar Sardesai
Publikováno v:
Journal of Clinical Oncology. 29:2240-2246
Purpose Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS). Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f119402af121b2020ae214f213063456
https://doi.org/10.1200/jco.2010.31.3353
https://doi.org/10.1200/jco.2010.31.3353
Autor:
Hagop M. Kantarjian, Jorge E. Cortes, Alfonso Quintás-Cardama, Srdan Verstovsek, Jianqin Shan, Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Lynne V. Abruzzo
Publikováno v:
Cancer. 117:5085-5093
BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258876c16a47ffdfb75fe8582bced031
https://doi.org/10.1002/cncr.26147
https://doi.org/10.1002/cncr.26147
Autor:
Sherry Pierce, Sarah Schellhorn Mougalian, Kiran Naqvi, Farshid Dayyani, Jianqin Shan, Susan O'Brien, Hagop M. Kantarjian, William G. Wierda, Deborah A. Thomas, Jorge E. Cortes, Guillermo Garcia-Manero, Elias Jabbour, Jeffrey S. Weinberg, Farhad Ravandi, Stefan Faderl
Publikováno v:
American Journal of Hematology. 86:546-549
Intracranial hemorrhage (ICH) is associated with great morbidity and mortality in patients with acute leukemia. We identified 118 patients with ICH from a total of 2,421 patient with leukemia who were treated at our institution between 2005–2009, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60666f20f51dd103b6f5a8a4cb601e0
https://doi.org/10.1002/ajh.22031
https://doi.org/10.1002/ajh.22031